Biovica International AB (publ) (FRA:9II)

Market Cap	9.84M +24.8%
Revenue (ttm)	1.04M +33.4%
Net Income	-6.79M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0036
Previous Close	0.0036
Day's Range	0.0036 - 0.0036
52-Week Range	0.0002 - 0.0538
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 17, 2026

About Biovica International AB

Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9II

Financial Performance

In fiscal year 2025, Biovica International AB's revenue was 8.65 million, an increase of 18.53% compared to the previous year's 7.30 million. Losses were -87.62 million, -29.80% less than in 2024.

Financial numbers in SEK